The 36-month beta value for TTOO is at 0.10. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 2 rating it as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for TTOO is 3.41M, and currently, shorts hold a 8.66% of that float. The average trading volume for TTOO on April 10, 2024 was 250.86K shares.
TTOO) stock’s latest price update
T2 Biosystems Inc (NASDAQ: TTOO) has experienced a rise in its stock price by 10.99 compared to its previous closing price of 2.82. However, the company has seen a gain of 5.74% in its stock price over the last five trading days. InvestorPlace reported 2024-03-12 that Shares of T2 Biosystems (NASDAQ: TTOO ) stock are rising higher after the medical diagnostics company disclosed that the Nasdaq Hearings Panel had provided it with an extension to regain compliance. T2 will have until May 20 to maintain a closing market capitalization of at least $35 million for at least 10 consecutive trading days.
TTOO’s Market Performance
T2 Biosystems Inc (TTOO) has experienced a 5.74% rise in stock performance for the past week, with a -36.25% drop in the past month, and a -44.99% drop in the past quarter. The volatility ratio for the week is 10.10%, and the volatility levels for the past 30 days are at 11.98% for TTOO. The simple moving average for the past 20 days is -7.19% for TTOO’s stock, with a -74.73% simple moving average for the past 200 days.
Analysts’ Opinion of TTOO
Many brokerage firms have already submitted their reports for TTOO stocks, with Alliance Global Partners repeating the rating for TTOO by listing it as a “Neutral.” The predicted price for TTOO in the upcoming period, according to Alliance Global Partners is $2.40 based on the research report published on January 27, 2021 of the previous year 2021.
BTIG Research, on the other hand, stated in their research note that they expect to see TTOO reach a price target of $2.50. The rating they have provided for TTOO stocks is “Buy” according to the report published on October 08th, 2020.
TTOO Trading at -29.06% from the 50-Day Moving Average
After a stumble in the market that brought TTOO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -95.53% of loss for the given period.
Volatility was left at 11.98%, however, over the last 30 days, the volatility rate increased by 10.10%, as shares sank -29.98% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -25.83% lower at present.
During the last 5 trading sessions, TTOO rose by +5.74%, which changed the moving average for the period of 200-days by -57.65% in comparison to the 20-day moving average, which settled at $3.31. In addition, T2 Biosystems Inc saw -50.12% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TTOO starting from CR Group L.P., who sale 7,148,945 shares at the price of $0.16 back on Sep 28 ’23. After this action, CR Group L.P. now owns 0 shares of T2 Biosystems Inc, valued at $1,125,959 using the latest closing price.
CR Group L.P., the 10% Owner of T2 Biosystems Inc, sale 5,981,202 shares at $0.19 during a trade that took place back on Sep 27 ’23, which means that CR Group L.P. is holding 571,796 shares at $1,145,998 based on the most recent closing price.
Stock Fundamentals for TTOO
Current profitability levels for the company are sitting at:
- -6.9 for the present operating margin
- -1.15 for the gross margin
The net margin for T2 Biosystems Inc stands at -7.25. The total capital return value is set at 2.33.
Based on T2 Biosystems Inc (TTOO), the company’s capital structure generated 2.31 points at debt to capital in total, while cash flow to debt ratio is standing at -0.97. The debt to equity ratio resting at -1.77. The interest coverage ratio of the stock is -15.99.
Currently, EBITDA for the company is -46.29 million with net debt to EBITDA at -0.68. When we switch over and look at the enterprise to sales, we see a ratio of 7.1. The receivables turnover for the company is 5.07for trailing twelve months and the total asset turnover is 0.21. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.45.
Conclusion
In conclusion, T2 Biosystems Inc (TTOO) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
